Eledon Pharmaceuticals, Inc.: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Nov 8, 2017 and accepted by EDGAR at Nov 8, 2017, 16:41 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2017-07-01 to 2017-09-30 | $517.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-01-01 to 2017-09-30 | $1.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-07-01 to 2017-09-30 | −$3.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-01-01 to 2017-09-30 | −$11.0m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2017-07-01 to 2017-09-30 | −$3.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-01-01 to 2017-09-30 | −$11.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-07-01 to 2017-09-30 | −$0.43 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2017-01-01 to 2017-09-30 | −$2.25 | us-gaap:EarningsPerShareBasicAndDiluted |
| Cash and equivalents | At period end2017-09-30 | $19.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $21.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $23.0m | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $2.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-09-30 | $2.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-09-30 | $20.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-17-022799. Last ingested by Listed: Nov 13, 2026, 16:16 ET. Listed shows no prices and gives no investment advice.